139 related articles for article (PubMed ID: 21163674)
21. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
22. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
23. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
Koukourakis MI; Tsoutsou PG; Abatzoglou I
Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
25. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
26. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
Chauvet B; Brewer Y; Félix-Faure C; Davin JL; Choquenet C; Reboul F
J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
[TBL] [Abstract][Full Text] [Related]
27. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
[TBL] [Abstract][Full Text] [Related]
28. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Rojas AM; Phillips H; Saunders MI
Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
[TBL] [Abstract][Full Text] [Related]
29. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
30. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
32. Whole Versus Partial Bladder Radiation: Use of an Image-guided Hypofractionated IMRT Bladder-preservation Protocol.
Kang JJ; Steinberg ML; Kupelian P; Alexander S; King CR
Am J Clin Oncol; 2018 Feb; 41(2):107-114. PubMed ID: 26535994
[TBL] [Abstract][Full Text] [Related]
33. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
[TBL] [Abstract][Full Text] [Related]
34. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
35. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
Singh AK; Ménard C; Guion P; Simone NL; Smith S; Crouse NS; Godette DJ; Cooley-Zgela T; Sciuto LC; Coleman J; Pinto P; Albert PS; Camphausen K; Coleman CN
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1008-13. PubMed ID: 16730138
[TBL] [Abstract][Full Text] [Related]
36. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
37. Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer.
Whalley D; Caine H; McCloud P; Guo L; Kneebone A; Eade T
Radiat Oncol; 2015 Sep; 10():205. PubMed ID: 26407726
[TBL] [Abstract][Full Text] [Related]
38. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
[TBL] [Abstract][Full Text] [Related]
39. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
40. Postoperative accelerated radiotherapy with cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer.
Koukourakis MI; Tsoutsou PG; Abatzoglou I; Soulimioti G; Sismanidou K; Liberis V; Giatromanolaki A; Sivridis E; Galazios G
Tumori; 2009; 95(4):455-60. PubMed ID: 19856656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
